The Secondary CNS Lymphoma drugs in development market research report provides comprehensive information on the therapeutics under development for Secondary CNS Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Secondary CNS Lymphoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Secondary CNS Lymphoma and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Secondary CNS Lymphoma by 12 companies/universities/institutes. The top development phase for Secondary CNS Lymphoma is phase ii with nine drugs in that stage. The Secondary CNS Lymphoma pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Secondary CNS Lymphoma pipeline products market are: AstraZeneca, Bristol-Myers Squibb and AbbVie.
The key targets in the Secondary CNS Lymphoma pipeline products market include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2), Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), and Protein Cereblon (CRBN).
The key mechanisms of action in the Secondary CNS Lymphoma pipeline product include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Inhibitor with six drugs in Phase II. The Secondary CNS Lymphoma pipeline products include four routes of administration with the top ROA being Oral and four key molecule types in the Secondary CNS Lymphoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Secondary CNS Lymphoma overview
Lymphoma in CNS (parts of the brain) is known as secondary CNS lymphoma (SCNSL). It is a form of CNS lymphoma where the risk of developing secondary lymphoma is 5-15%. It involves brain, eyes, spinal cord, meninges, as these are BBB (blood brain barriers) it creates a therapeutic challenge in managing this condition while relapse of the condition is also seen. Diagnosed during the initial setting of lymphoma where primary symptoms are presented based on the location of lymphoma. Seizures, irritability, headache, nausea and vomiting, difficulty with memory, confusion all the CNS related signs and symptoms are presented. It is diagnosed by biopsy of the effected tissue, radiographic examinations MRI, CT scan, lumbar punction, CSF examination are performed. Induction therapy and consolidation therapy are the treatment options as there is no standard treatment protocol. Chemotherapy drugs with combination are given followed by chemo with radiation therapy are steroids. Prophylaxis treatment to manage the complications associated with the condition.
For a complete picture of Secondary CNS Lymphoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
